$VIVS

VivoSim Labs (NASDAQ: VIVS) filed a preliminary proxy seeking stockholder approval at a fully virtual Sept. 30, 2026 annual meeting. Proposals include electing two directors, ratifying Rosenberg Rich Baker Berman P.A. as auditor, a say-on-pay vote, authorizing a board-discretionary reverse split, amending its 2022 equity plan, and approving warrant-related share issuance up to 4,705,883 shares.

VIVOSIM LABS (VIVS) is set to report Q1 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts expect revenue of $47.94 million and EPS of -$0.19. The article also cites recent institutional activity, including adds by Geode Capital and Goldman Sachs and reductions by Citadel and Two Sigma.

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

VivoSim Labs (VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) after meeting the $2.5 million minimum stockholders’ equity requirement. The company cited post–March 31 and June 30 events, including a $5.0 million milestone from Eli Lilly, $1.0 million escrow release, and a July 17 financing with $4.0 million gross proceeds. Cash was about $10.1 million as of Aug. 3, 2026, and it reiterated 500%+ fiscal 2027 revenue growth guidance.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001497253 0001497253 2026-08-06 2026-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

VivoSim Labs said Nasdaq notified it on July 20, 2026 that it failed Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and it did not qualify under alternative standards. The company has 45 days to submit a compliance plan, with a possible extension to Jan. 16, 2027. Trading remains on Nasdaq under VIVS.

VivoSim Labs (Nasdaq: VIVS) said it began its first commercial sales in mainland China for its NAMkind toxicology and efficacy testing services. Two orders via local distributor Tekon cover GI toxicology screening and GI efficacy profiling for oncology candidate molecules, with the company calling them its first paid programs in China. VivoSim cites NMPA innovation approvals and FDA animal-testing phaseout plans.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 d134319dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 16, 2026, between VivoSim Labs, Inc., a Delaware corporation (the “ Company ”), and each of the purchasers identified

VivoSim Labs (NASDAQ:VIVS) said it signed a securities purchase agreement to sell 4.71 million shares and warrants to a healthcare-focused institutional investor at an effective $0.85 per share, raising about $4.0 million gross. New warrants are exercisable at $0.85 for five years, and the company plans to amend May 2024 warrants to lower the exercise price to $0.85 and extend terms, pending approval. Shares were down 26.52% to $0.62.